The Effect Of Lersivirine (UK-453,061) On Qt Intervals In Healthy Subjects

• Drug: Lersivirine
  Lersivirine 2400 mg single dose
• Drug: Placebo
  Placebo single dose
• Drug: Lersivirine (if necessary)
  Lersivirine 2100 mg single dose (if necessary)
• Drug: Lersivirine
  Lersivirine 2400 mg single dose (dose may be decreased pending Part A tolerability results)
• Drug: Moxifloxacin
  Moxifloxacin 400 mg single dose

• Experimental: Part A
  Lersivirine Tolerability
  Interventions:

  • Drug: Lersivirine
  • Drug: Placebo
  • Drug: Lersivirine (if necessary)
• Experimental: Part B
  Thorough QTc
  Interventions:

  • Drug: Lersivirine
  • Drug: Placebo
  • Drug: Moxifloxacin

Inclusion Criteria:

• Healthy male and/or female subjects between the ages of 18 and 55 years, inclusive, (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, normal 12-lead ECG and clinical laboratory tests)

Exclusion Criteria:

• History of risk factors for QT prolongation or torsades de pointes (eg, organic heart disease, congestive heart failure, hypokalemia, hypomagnesemia, congenital long QT syndrome, myocardial ischemia or infarction).
• Use of tobacco- or nicotine-containing products in excess of the equivalent of 5 cigarettes per day
• Use of prescription or nonprescription drugs, vitamins and dietary supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of trial medication.